Ignite Creation Date:
2024-05-05 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00007189
Status:
COMPLETED
Last Update Posted:
2016-10-19
First Post:
2000-12-14
Brief Title:
Alzheimers Disease Anti-Inflammatory Prevention Trial ADAPT
Sponsor:
Seattle Institute for Biomedical and Clinical Research
Organization:
Seattle Institute for Biomedical and Clinical Research
Study Overview
Official Title:
Alzheimers Disease Anti-Inflammatory Prevention Trial ADAPT
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to test the ability of the non-steroidal anti-inflammatory medications naproxen and celecoxib to delay or prevent the onset of AD and age-related cognitive decline
Detailed Description:
Considerable evidence suggests that inflammation may play a role in the neurodegenerative process of Alzheimers disease AD and the use of non-steroidal anti-inflammatory drugs may be associated with reduced occurrence of AD ADAPT is a randomized trial that will test the ability of the non-steroidal anti-inflammatory medications naproxen and celecoxib to delay or prevent the onset of AD and age-related cognitive decline This long-term trial will run for 5 to 7 years
The study is sponsored by the National Institute on Aging and is being conducted at the Roskamp Institute in Tampa FL the Veterans Affairs Puget Sound Health Care System with the University of Washington in Seattle WA Boston University School of Medicine in Boston MA the Johns Hopkins Medical Institutions in Baltimore MD Sun Health Research Institute in Phoenix AZ and the University of Rochester in Rochester NY At each of these six sites the goal is the enroll approximately 700 men and women totalling 2625 participants Participants must be 70 years of age or older have a parent brother or sister who has or had serious age-related memory loss senility dementia or Alzheimers disease
Participants will be asked to take an anti-inflammatory medication or placebo inactive pill twice daily Before enrolling in the trial participants will be asked to go to a study site for two medical evaluations Once enrolled they will need to go to a study site for a medical evaluation every six months and to participate in a telephone interview twice a year for an average of up to seven years of follow-up
The study is sponsored by the National Institute on Aging and is being conducted at the Roskamp Institute in Tampa FL the Veterans Affairs Puget Sound Health Care System with the University of Washington in Seattle WA Boston University School of Medicine in Boston MA the Johns Hopkins Medical Institutions in Baltimore MD Sun Health Research Institute in Phoenix AZ and the University of Rochester in Rochester NY At each of these six sites the goal is the enroll approximately 700 men and women totalling 2625 participants Participants must be 70 years of age or older have a parent brother or sister who has or had serious age-related memory loss senility dementia or Alzheimers disease
Participants will be asked to take an anti-inflammatory medication or placebo inactive pill twice daily Before enrolling in the trial participants will be asked to go to a study site for two medical evaluations Once enrolled they will need to go to a study site for a medical evaluation every six months and to participate in a telephone interview twice a year for an average of up to seven years of follow-up
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U01AG015477 | NIH | None | httpsreporternihgovquickSearchU01AG015477 |